Altamira Therapeutics Ltd. Deferred Tax Expense Income
Altamira Therapeutics Ltd. (CYTOF) reported Deferred Tax Expense Income of CHF 900.00 thousand for the 12-month period ending 2022-12-31, per its 20-F/A filed 2024-04-22.
Discontinued › Expense Statement › Operating Expenses
ifrs-full:DeferredTaxExpenseIncome · last filed 2024-04-22
CHF
| Period end | Deferred Tax Expense Income 12 month |
|---|---|
| 2022-12-31 | 900.00K CHF 20-F/A · filed 2024-04-22 |
USD
| Period end | Deferred Tax Expense Income 12 month |
|---|---|
| 2022-12-31 | $1.00M 20-F/A · filed 2024-04-22 |